
Immuneering Corporation Class A Common Stock
IMRX
IMRX: Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to leading pharmaceutical and biotechnology companies.
moreShow IMRX Financials
Recent trades of IMRX by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by IMRX's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Systems and methods for rapid gene set enrichment analysis Jun. 22, 2021
Federal grants, loans, and purchases
Followers on IMRX's company Twitter account
Number of mentions of IMRX in WallStreetBets Daily Discussion
Recent insights relating to IMRX
Recent picks made for IMRX stock on CNBC
ETFs with the largest estimated holdings in IMRX
Flights by private jets registered to IMRX